NAMS 250516 22.50C(NAMS250516C22500) Stock Price Today

US OptionsDetailed Quotes

NAMS250516C22500

Watchlist

1.00
+0.70+233.33%

15min DelayClose May 5 16:00 ET

1.00High1.00Low

Intraday

5D
Daily

News

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
GlobeNewswireApr 30 08:00 ET
NewAmsterdam Pharma Company N.V. (NAMS): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential
Yahoo FinanceApr 29 11:40 ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
BenzingaApr 22 17:05 ET
Press Release: NewAmsterdam Pharma Appoints Adele Gulfo to Its Board of Directors
Dow JonesApr 17 16:01 ET
Express News | NewAmsterdam Pharma Appoints Adele Gulfo to Its Board of Directors
ReutersApr 17 16:01 ET
Jefferies Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $45
Moomoo NewsApr 16 14:31 ET · Ratings

Comments

Teddy123

Apr 30 20:09

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

$NewAmsterdam Pharma (NAMS.US)$
Major Breakthrough: NewAmsterdam Reveals Multiple Phase 3 Trial Results for Novel Heart Drug

10xStockPicks

Feb 21 21:57

Esperion Therapeutics On The Verge Of Being Acquired, Upside Could Be Over 500% In The Near Future

$Esperion Therapeutics (ESPR.US)$Esperion Therapeutics (ESPR): A High-Growth Opportunity with Potential 10x Returns
Esperion Therapeutics (ESPR), currently trading under $2 per share, has been attracting considerable attention from analysts. Recently, three analysts reaffirmed strong "Buy" ratings, with price targets ranging from $5 to $16 per share. Among the nine analysts covering Esperion, seven h...

10xStockPicks

Dec 16, 2024 08:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 16, 2024 05:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

103848509

Dec 10, 2024 21:21

$NewAmsterdam Pharma (NAMS.US)$ niceerr high fly prolly